Marshall Wace LLP purchased a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,554 shares of the company’s stock, valued at approximately $390,000. Marshall Wace LLP owned 0.62% of LENZ Therapeutics at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in LENZ. RA Capital Management L.P. bought a new stake in shares of LENZ Therapeutics in the 1st quarter valued at about $93,313,000. Vanguard Group Inc. bought a new stake in LENZ Therapeutics during the 1st quarter valued at $4,621,000. Jennison Associates LLC purchased a new position in shares of LENZ Therapeutics in the 1st quarter valued at $3,009,000. Ikarian Capital LLC bought a new position in shares of LENZ Therapeutics in the 1st quarter worth $1,898,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of LENZ Therapeutics during the 2nd quarter worth $1,437,000. 54.32% of the stock is currently owned by institutional investors.
LENZ Therapeutics Stock Down 3.5 %
NASDAQ LENZ opened at $23.60 on Friday. LENZ Therapeutics, Inc. has a 12-month low of $14.07 and a 12-month high of $29.82. The company has a fifty day simple moving average of $22.87 and a two-hundred day simple moving average of $20.04.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on LENZ shares. HC Wainwright began coverage on LENZ Therapeutics in a research note on Monday, August 12th. They issued a “buy” rating and a $38.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $36.00 target price on shares of LENZ Therapeutics in a research report on Thursday, August 15th. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Raymond James began coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $35.40.
Get Our Latest Research Report on LENZ
LENZ Therapeutics Profile
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Articles
- Five stocks we like better than LENZ Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Why Are These Companies Considered Blue Chips?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding LENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report).
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.